You are here

Home Personalized medicine for patients with Acute Myeloid Leukemia (AML) and high risk myelodysplastic syndrome (MDS).

Personalized medicine for patients with Acute Myeloid Leukemia (AML) and high risk myelodysplastic syndrome (MDS).

created by bccf on June 29, 2011

To provide detection of genetic abnormalities in malignant cells of patients with AML and MDS.

Fund Type: 
Funding Priorities